Taysha Gene Therapies (NASDAQ: TSHA) insider files to sell shares

Rhea-AI Filing Summary

Taysha Gene Therapies insider plans small stock sale under Rule 144. A person associated with the company filed to sell 697 shares of common stock through Maxim Group LLC on Nasdaq, with an aggregate market value of $3,289.84, against 273,919,373 shares outstanding.

The shares were acquired on 02/03/2026 via a restricted stock unit (RSU) award that vested and settled in stock in exchange for continued employment. During the prior three months, the same seller disposed of 23,533 shares for $111,781.75 and 7,107 shares for $32,763.27.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 06:39 PM Learn about SEC filing dates

FAQ

What does the TSHA Form 144 filing disclose?

The filing discloses a planned sale of 697 shares of Taysha Gene Therapies common stock. The shares have an aggregate market value of $3,289.84 and are expected to be sold on Nasdaq through Maxim Group LLC under Rule 144.

Who is selling TSHA shares and in what amount?

The seller is Rumana Haque-Ahmed, associated with Taysha Gene Therapies. The current notice covers 697 common shares. In the past three months, the same seller also disposed of 23,533 and 7,107 shares in separate transactions.

How were the TSHA shares in this Form 144 acquired?

The 697 Taysha Gene Therapies shares were acquired on 02/03/2026 via an RSU award. The award vested and settled in stock, with consideration described as the reporting person’s continued service as an employee of the issuer.

What prior TSHA stock sales has this insider made recently?

In the last three months, the insider sold 23,533 shares of Taysha Gene Therapies common stock on 01/23/2026 for $111,781.75, and 7,107 shares on 01/26/2026 for $32,763.27, according to the disclosure.

How many TSHA shares are outstanding in this Form 144?

The notice states that 273,919,373 shares of Taysha Gene Therapies common stock are outstanding. This figure is provided as context for the planned Rule 144 sale of 697 shares by the reporting person.

On which exchange will the TSHA shares be sold under this notice?

The filing indicates that the 697 Taysha Gene Therapies common shares are expected to be sold on the Nasdaq market. Maxim Group LLC, based in New York, is listed as the broker handling the planned Rule 144 transaction.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	697	3289.84	273919373	02/04/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/03/2026	RSU Award	Issuer			697	02/03/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Rumana Haque-Ahmed c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/23/2026	23533	111781.75
Rumana Haque-Ahmed c/o Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas TX 75247	Common Stock	01/26/2026	7107	32763.27

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)